Xilio Therapeutics GAAP EPS of -$0.11 misses by $0.08, revenue of $19.07M beats by $0.43M
Source: SeekingAlpha
2025-11-13 12:25:29 ET
More on Xilio Therapeutics
- Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC - Slideshow
- Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC Transcript
- Seeking Alpha’s Quant Rating on Xilio Therapeutics
- Historical earnings data for Xilio Therapeutics
- Financial information for Xilio Therapeutics
Read the full article on Seeking Alpha
For further details see:
Xilio Therapeutics GAAP EPS of -$0.11 misses by $0.08, revenue of $19.07M beats by $0.43M
Xilio Therapeutics Inc.
NASDAQ: XLO
XLO Trading
0.94% G/L:
$0.538 Last:
45,543 Volume:
$0.5401 Open:
XLO Latest News
March 02, 2026 08:00:00 am
Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference
January 08, 2026 08:30:00 am
Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates
November 13, 2025 07:30:00 am
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results
XLO Stock Data
$36,573,414
29,954,402
2.14%
13
N/A
Biotechnology & Life Sciences
Healthcare
US
Waltham
